A Phase Ⅲ Comparative Study of QL2108 to Dupixent®

Clinical trial NCT06884891 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06884891
Sponsor: Qilu Pharmaceutical Co., Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Atopic Dermatitis

Start date: 2025-04-01
Primary completion: 2027-05-01
Enrollment: 520

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.